Periodic Reporting for period 1 - StrokeFlow (Empowering physicians to provide every stroke treatment with the right treatment in time, with StrokeFlow)
Période du rapport: 2023-03-01 au 2024-02-29
One in five people suffer a stroke. Stroke is the no. 1 cause of severe long-term disability. Every minute the treatment is delayed, 22 healthy living days are lost, making it the most time-critical disease. Rapid treatment is vital to decrease mortality and disability rates.
Despite the introduction of promising new stroke therapies in recent years, functional outcome of stroke patients has barely improved since 2000 – while deaths have almost halved, still half of patients become severely or heavily disabled (unchanged from 2000) with €80B costs in EU alone per year.
The reason for this is that stroke care specialists are literally left in the dark when it comes to diagnosing and treating stroke patients. The accurate and time-critical selection of the optimal stroke treatment is currently impossible and as a result, all patients are treated in a one-size-fits-all process as essential insights are unavailable to tailor treatments to patient needs.
Nicolab wants to drastically reduce the time to intervention while increasing the quality of the intervention itself, leading to better post-stroke quality of life, cost reductions, and less societal burden. We propose a paradigm shifting solution called StrokeFlow to enable stroke care specialists to, for the first time, make true personalized treatment decisions in the hyper acute setting. With revolutionary technology we identify the necessary physiological aspects with unprecedented accuracy within minutes. Physicians will finally be able to treat patients with the most accurate information available.
Despite the introduction of promising new stroke therapies in recent years, functional outcome of stroke patients has barely improved since 2000 – while deaths have almost halved, still half of patients become severely or heavily disabled (unchanged from 2000) with €80B costs in EU alone per year.
The reason for this is that stroke care specialists are literally left in the dark when it comes to diagnosing and treating stroke patients. The accurate and time-critical selection of the optimal stroke treatment is currently impossible and as a result, all patients are treated in a one-size-fits-all process as essential insights are unavailable to tailor treatments to patient needs.
Nicolab wants to drastically reduce the time to intervention while increasing the quality of the intervention itself, leading to better post-stroke quality of life, cost reductions, and less societal burden. We propose a paradigm shifting solution called StrokeFlow to enable stroke care specialists to, for the first time, make true personalized treatment decisions in the hyper acute setting. With revolutionary technology we identify the necessary physiological aspects with unprecedented accuracy within minutes. Physicians will finally be able to treat patients with the most accurate information available.
- Since the start of the project in March 2023, we have made significant progress toward realizing our goals. Concretely, we have developed, tested, optimized and implemented the following main features:
o First version of digital clot biopsy technology
o Algorithm improvements for MeVO detection
o First algorithms developed and tested for core and penumbra volume calculations
o Integration efforts towards real-time interfacing with Philips Angio Suite equipment
o Development and implementation of a platform and company wide UX design language
o Multiple end user tests and pilots in the context of new features
o First version of digital clot biopsy technology
o Algorithm improvements for MeVO detection
o First algorithms developed and tested for core and penumbra volume calculations
o Integration efforts towards real-time interfacing with Philips Angio Suite equipment
o Development and implementation of a platform and company wide UX design language
o Multiple end user tests and pilots in the context of new features
Although patentability of the novel features is yet to be fully determined, it is clear that our technological focus is resulting in unique and cutting-edge features. Our main focus and USP of the project relates to the digital clot biopsy technology, which time and again immediately impresses end users when they see it for the first time, even though it is still a prototype. This feature has the potential to be a complete spin off product due to its immense potential impact, as it can also be used by device manufactures – an avenue that we are currently exploring. Currently, the technical and clinical accuracy are still lacking, which will be the main technical effort of the coming months.